🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Poland / NCT07235215
Recruiting Not applicable

Vivatlac in Irritable Bowel Syndrome II (ViIBS2)

NCT07235215 · tracked via the Priya Life Science Poland tracker
Sponsor
The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Phase
Not applicable
Started
2025-11-21
Last updated
2025-12-15

Condition(s) studied

Irritable Bowel Syndrome

Investigational drug(s) / intervention(s)

Vivatlac SynbioticPlacebo

Vivatlac Synbiotic: Vivatlac Synbiotic containing a total of 4.5 x 10\^9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10\^8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10\^8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10\^8 CFU; Bifidobacterium longum ES1, 4.50 x 10\^8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10\^8 CFU; Streptococcus thermophiles St-21, 4.50 x 10\^8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10\^8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10\^8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10\^8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.

Placebo: Capsule containing maize starch with identical appearance as verum.

Study summary

Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosed for Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization * IBS-SSS ≥ 175 points Exclusion Criteria: * patients currently taking products containing probiotics or have taken this kind of products during the last 3 months * patients currently taking antibiotics or have taken antibiotics during the last 3 months * patients having a concurrent severe illness (malignancies, uncontrolled hypertension or diabetes, hepatic, renal or cardiac dysfunctions, serious neurological disorders, psychosis, respiratory disorders such as asthma or COPD, hyper- or hypothyroidism * patients having chronic bowel disorders other than IBS, including inflammatory bowel disease, gastroenteritis, stomach and duodenal cancer, celiac disease * patient being pregnant, lactating, or planning to become pregnant during the next 9 months * patient being diagnosed to have a lactose intolerance * patients using motility drugs or dietary fiber supplements withing 2 weeks before study start * patient taking anti-coagulant medication * patients have participated in another clinical trial within the last three months

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
District Hospital Jarocin Jarocin Poland Recruiting
GP Clinic Spitalna Jarocin Poland Recruiting
GP Clinic Wroclawska Jarocin Poland Recruiting

More The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07235215 on ClinicalTrials.gov ↗ ← All trials in Poland